Efficacy of Liquid-chromatography and Radioimmunoassay in False-positives’ Drop-off in CAH Newborn Screening
Open Access
- 11 March 2026
- journal article
- other
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (8) , 2210-2219
Abstract
Context The main challenge in congenital adrenal hyperplasia newborn screening (CAH-NBS) is the high rate of false-positive (FP) results, emphasizing the need for specific serum confirmatory tests. Data on the effectiveness of serum 17-hydroxyprogesterone (17OHP) measurements using available methodologies remain limited. Objectives to evaluate the efficacy of confirmatory tests using measurements of serum steroids by radioimmunoassay (RIA) and liquid chromatography tandem mass spectrometry (LC-MS/MS) methodologies. Design and Setting A prospective longitudinal cohort study. Patients data of 708,437 newborns (NBs) were evaluated. Methods neonatal-17OHP (N17OHP) results ≥ 2x 99.5th were recalled for serum dosages by RIA (17OHP), by LC-MS/MS (17OHP, 21-deoxycortisol-21DF, androstenedione-Δ4, cortisol) and positive predictive values (PPV) were determined. Altered hormonal results were submitted to CYP21A2 genotyping. Non-parametric tests and ROC-curves were used. Results Recall rate of N17OHP (first tier) was 0.03% and serum 17OHP levels remained increased in 26% (RIA) and 11% (LC-MS/MS) of NBs, yielding PPV of 30% and 49%, respectively. Fifty-eight NBs were diagnosed with classical forms, and 32 asymptomatic-NBs persisted with increased serum 17OHP levels. ROC-curves between false and true-positive tests disclosed highest diagnostic performance for 17OHP/LC-MS/MS [cutoff 48.3 ng/mL (146.3 nmol/L) = 100%-sensitivity]. The (17OHP+Δ4)/cortisol ratio presented the highest discriminative ability (cutoff 24.9 = 100%-PPV); serum 21DF presented a good performance and was comparable to 17OHP measured by LC–MS/MS (99%-specificity). Conclusion Measurement of 17OHP by LC-MS/MS provides the best performance for serum confirmatory tests and may be complemented by the (17OHP+Δ4)/cortisol ratio analysis. Genotyping is useful mainly to resolve persistently indeterminate biochemical results.Keywords
Funding Information
- Fundação de Amparo à Pesquisa do Estado de São Paulo (#2014/07878-4)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (#2023/11168-1)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (#2023/16309-2)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (#303183/2020-9)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (#307571/2021-1)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (#308871/2022-7)
This publication has 42 references indexed in Scilit:
- Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) Method for the Quantification of Steroids Androstenedione, Dehydroepiandrosterone, 11-Deoxycortisol, 17-Hydroxyprogesterone, and Testosterone2022
- The progression of salt‐wasting and the body weight change during the first 2 weeks of life in classical 21‐hydroxylase deficiency patientsClinical Endocrinology, 2020
- Clinical Impact and Cost Efficacy of Newborn Screening for Congenital Adrenal HyperplasiaThe Journal of Pediatrics, 2020
- Neonatal 17‐hydroxyprogesterone levels adjusted according to age at sample collection and birthweight improve the efficacy of congenital adrenal hyperplasia newborn screeningClinical Endocrinology, 2017
- Nationwide Neonatal Screening for Congenital Adrenal Hyperplasia in SwedenJAMA Pediatrics, 2014
- Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency: From Birth to AdulthoodSeminars in Reproductive Medicine, 2012
- Cases of Congenital Adrenal Hyperplasia Missed by Newborn Screening in MinnesotaJAMA, 2012
- Rapid steroid hormone quantification for congenital adrenal hyperplasia (CAH) in dried blood spots using UPLC liquid chromatography–tandem mass spectrometrySteroids, 2011
- Serum steroid profiling for Congenital Adrenal Hyperplasia using liquid chromatography–tandem mass spectrometryClinica Chimica Acta, 2010
- Reduction of the false‐positive rate in newborn screening by implementation of MS/MS‐based second‐tier tests: The Mayo Clinic experience (2004–2007)Journal of Inherited Metabolic Disease, 2007